







FIG. 2



*Based on patients with positive gene signature at baseline.
Positive is defined as baseline 21-gene signature ≥ 2

FIG. 3A




FIG. 3B




FIG. 4A




FIG. 4B




FIG. 5A




FIG. 5B




FIG. 6A




FIG. 6B




FIG. 7A
IL-10H/IFN-H





FIG. 7B
IL-10L/IFN-H



8/66

FIG. 8A




FIG. 8B






FIG. 9




	Conditions	N	Stats (Wilcoxon)		
Group 1	1.5>X	75	vs Group 1	vs Group 2	vs Group 3
Group 2	1.5<X<=2.5	82	P<.001		
Group 3	2.5<X<=3.8	68	P<.001	...	
Group 4	X>=3.8	72	P<.001	P<.01	P<.01

FIG. 10




	Conditions	N	Stats (Wilcoxon)		
Group 1	1.5>X	78	vs Group 1	vs Group 2	vs Group 3
Group 2	1.5<X<=2.5	84	...		
Group 3	2.5<X<=3.8	72	...	...	
Group 4	X>=3.8	77	P<.01	P<.05	P<.05

FIG. 11




	Conditions	N	Stats (Wilcoxon)		
Group 1	1.5>X	78	vs Group 1	vs Group 2	vs Group 3
Group 2	1.5<X<=2.5	84	...		
Group 3	2.5<X<=3.8	72	...	...	
Group 4	X>=3.8	77	P<.001	P<.001	P<.001

FIG. 12



	Conditions	N	Stats (Wilcoxon)		
Group 1	IFNGSH/IL10L	78	vs Group 1	vs Group 2	vs Group 3
Group 2	IFNGSH/IL10H	84	P<.01		
Group 3	IFNGSL/IL10L	72	P<.01	P<.01	
Group 4	IFNGSL/IL10H	77	...	P<.01	...

FIG. 13



	Conditions	N	Stats (Wilcoxon)		
Group 1	1.5>X	78	vs Group 1	vs Group 2	vs Group 3
Group 2	1.5<X<=2.5	84	...		
Group 3	2.5<X<=3.8	72	P<.05	...	
Group 4	X>=3.8	77	P<.001	P<.01	P<.01

FIG. 14




FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19A




FIG. 19B




FIG. 20




FIG. 21






FIG. 22




X axis	IL-10; new data (2018), DAY 1, Absolute (geometric mean)				
Y axis	gene21 FOLD CHANGE, DAY 1, Absolute (geometric mean)				
Doses	Dose0=Y; Dose300=Y; Dose1000=Y				
LLOQ	Points <= LLOQ are included				
	Conditions (auto)	Points N	Statistics (P values, Student's test)		
Group 1	1.38>X	52	vs Group 1	vs Group 2	vs Group 3
Group 2	2.13>X>=1.38	84	P<0.01		
Group 3	3.53>X>=2.13	67	P<0.001	P<0.001	
Group 4	X>=3.53	50	P<0.001	P<0.001	P<0.05

FIG. 23




X axis	IL-10; new data (2018), DAY1, Absolute (geometric mean)				
Y axis	TOTAL SLEDAI 2K SCORE, DAY 1, Absolute (arithmetic mean)				
Doses	Dose0=Y; Dose300=Y; Dose1000=Y				
LLOQ	Points <= LLOQ are included				
	Conditions (auto)	Points N	Statistics (P values, Student's test)		
Group 1	1.38>X	53	vs Group 1	vs Group 2	vs Group 3
Group 2	2.13>X>=1.38	84	...		
Group 3	3.53>X>=2.13	67	P<0.01	P<0.001	
Group 4	X>=3.53	50	P<0.001	P<0.001	...

FIG. 24




X axis	IL-10; new data (2018), DAY1, Absolute (geometric mean)				
Y axis	ANTI-DSDNA, DAY 1, Absolute (arithmetic mean)				
Doses	Dose0=Y; Dose300=Y; Dose1000=Y				
LLOQ	Points <= LLOQ are included				
	Conditions (auto)	Points N	Statistics (P values, Student's test)		
Group 1	1.39>X	51	vs Group 1	vs Group 2	vs Group 3
Group 2	2.13>X>=1.39	84	...		
Group 3	3.53>X>=2.13	66	P<0.001	P<0.001	
Group 4	X>=3.53	49	P<0.001	P<0.001	...

FIG. 25




X axis	IL-10; new data (2018), DAY1, Absolute (geometric mean)				
Y axis	IMMUNOGLOBULIN G, DAY 1, Absolute (arithmetic mean)				
Doses	Dose0=Y; Dose300=Y; Dose1000=Y				
LLOQ	Points <= LLOQ are included				
	Conditions (manual)	Points N	Statistics (P values, Student's test)		
Group 1	1.5>X	64	vs Group 1	vs Group 2	vs Group 3
Group 2	2.5>X>=1.5	92	P<0.05		
Group 3	3.5>X>=2.5	44	P<0.001	...	
Group 4	X>=3.5	53	P<0.001	P<0.05	...

FIG. 26




X axis	IL-10; new data (2018), DAY1, Absolute (geometric mean)				
Y axis	IFN-alpha; new data (2018), DAY 1, Absolute (geometric mean)				
Doses	Dose0=Y; Dose300=Y; Dose1000=Y				
LLOQ	Points <= LLOQ are included				
	Conditions (auto)	Points N	Statistics (P values, Student's test)		
Group 1	1.38>X	53	vs Group 1	vs Group 2	vs Group 3
Group 2	2.13>X>=1.38	84	...		
Group 3	3.53>X>=2.13	67	P<0.05	...	
Group 4	X>=3.53	50	P<0.001	P<0.05	P<0.05

FIG. 27A




X axis	IL-10; new data (2018), DAY 1, Absolute (geometric mean)				
Y axis	LYMPHOCYTES ABSOLUTE, DAY 1, Absolute (geometric mean)				
Doses	Dose0=Y; Dose300=Y; Dose1000=Y				
LLOQ	Points <= LLOQ are included				
	Conditions (auto)	Points N	Statistics (P values, Student's test)		
Group 1	1.38>X	51	vs Group 1	vs Group 2	vs Group 3
Group 2	2.13>X>=1.38	83	...		
Group 3	3.52>X>=2.13	66	P<0.001	P<0.05	
Group 4	X>=3.52	49	P<0.001	P<0.001	P<0.001

FIG. 27B




X axis	IL-10; new data (2018), DAY 1, Absolute (geometric mean)				
Y axis	NEUTROPHILS, ABSOLUTE, DAY 1, Absolute (geometric mean)				
Doses	Dose0=Y; Dose300=Y; Dose1000=Y				
LLOQ	Points <= LLOQ are included				
	Conditions (auto)	Points N	Statistics (P values, Student's test)		
Group 1	1.38>X	51	vs Group 1	vs Group 2	vs Group 3
Group 2	2.13>X>=1.38	83	P<0.05		
Group 3	3.52>X>=2.13	66	...	P<0.05	
Group 4	X>=3.52	49	...	...	...

FIG. 28



X axis	IFNGS-IL10 strat. (1=IFN-high/IL10-low; 2=IFN-high/IL10-high; 3=IFN-low/IL10-low; 4=IFN-low/IL1-high), DAY 1, Absolute (mean)				
Y axis	ANTI-DSDNA, DAY 1, Absolute (geometric mean)				
Doses	Dose0=Y; Dose300=Y; Dose1000=Y				
LLOQ	Points <= LLOQ are included				
	Conditions (manual)	Points N	Statistics (P values, Student's test)		
Group 1	1.5>X	71	vs Group 1	vs Group 2	vs Group 3
Group 2	2.5>X>=1.5	119	P<0.001		
Group 3	3.5>X>=2.5	49	...	P<0.001	
Group 4	X>=3.5	11	...	...	...

FIG. 29



X axis	IFNGS-IL10 strat. (1=IFN-high/IL10-low; 2=IFN-high/IL10-high; 3=IFN-low/IL10-low; 4=IFN-low/IL1-high), DAY 1, Absolute (mean)				
Y axis	TOTAL SLEDAI 2K SCORE, DAY 1, Absolute (arithmetic mean)				
Doses	Dose0=Y; Dose300=Y; Dose1000=Y				
LLOQ	Points <= LLOQ are included				
	Conditions (manual)	Points N	Statistics (P values, Student's test)		
Group 1	1.5>X	71	vs Group 1	vs Group 2	vs Group 3
Group 2	2.5>X>=1.5	120	P<0.001		
Group 3	3.5>X>=2.5	51	...	P<0.001	
Group 4	X>=3.5	12	...	...	...

FIG. 30A




FIG. 30B




FIG. 30C




FIG. 30D




FIG. 31




FIG. 32




FIG. 33





FIG. 34



37/66

FIG. 35A

		Pbo	300 mg Ani	300 mg vs Pbo		1000 mg Ani	1000 mg vs Pbo	
				OR	p		OR	p
IFNGS test-high	IL10-low	6/23 (26.1%)	16/23 (69.6%)	6.48	0.004	15/25 (60%)	4.25	0.02
	IL10-high	8/36 (22.2%)	19/43 (44.2%)	2.77	0.04	15/41 (36.6%)	2	0.2
IFNGS test-low		11/26 (42.3%)	12/24 (50%)	1.36	0.6	10/26 (38.5%)	0.85	0.5

FIG. 35B




FIG. 35C




FIG. 35D




FIG. 35E






FIG. 36



39/66

FIG. 37A

IFNGS test-low

**FIG. 37B**

IFNGS test-high




FIG. 38A




FIG. 38B




FIG. 38C




FIG. 38D




FIG. 39





FIG. 40



Nominal P-values are presented for pooled data
*P<0.05, **P<0.01, ***P<0.001

FIG. 41A




FIG. 41B




FIG. 41C




FIG. 41F




FIG. 41E





FIG. 41D






FIG. 43A




FIG. 43B




FIG. 43C




FIG. 44




FIG. 45




FIG. 46A




FIG. 46B




FIG. 47





FIG. 48



Number at risk in TULIP-2													
Anifrolumab 300 mg	179	175	158	153	147	141	138	130	124	118	116	114	103
Placebo	181	167	159	149	137	120	113	107	98	97	95	91	77

Number at risk in TULIP-1													
Anifrolumab 300 mg	180	171	162	151	139	131	124	117	114	105	101	100	87
Placebo	184	181	170	159	149	123	120	111	103	96	91	89	70

FIG. 49




FIG. 50




FIG. 51




FIG. 52





FIG. 53



Favors placebo -10 0 10 20 30 40 50 Favors anifrolumab

CLASI, Cutaneous Lupus Erythematosus Disease Area and Severity Index; CLASI-A, CLASI activity score. Baseline is defined as the last measurement before randomization and investigational product dose administration on Day 1. The difference in estimates and associated 95% CIs are calculated using a stratified Cochran-Mantel-Haenszel approach. The nominal P-values presented are based on this Cochran-Mantel-Haenszel model.

FIG. 54




FIG. 55A




FIG. 55B




FIG. 55C




FIG. 55D




FIG. 56A





FIG. 56B







FIG. 57A





FIG. 57B



65/66

FIG. 58A




FIG. 58B




FIG. 58C




FIG. 59A

Disease activity measure		Placebo (n=66)	Anifrolumab 300 mg (n=84)	Anifrolumab 1000 mg (n=73)
SLEDAI-2K score	Week 52, mean	5.9	4.3	3.8
	Week 60, mean	5.8	5.0	4.1
	Mean change (SD) ^a	-0.1 (2.4)	0.7 (3.5)	0.3 (2.3)
BILAG- 2004 score	Week 52, mean	8.3	6.0	5.9
	Week 60, mean	9.1	8.5	6.6
	Mean change (SD) ^a	0.8 (3.8)	2.4 (6.7)	0.7 (5.3)
CLASI activity score	Week 52, mean	3.5 ^b	1.9	1.8
	Week 60, mean	4.0 ^b	2.4	2.2
	Mean change (SD) ^a	0.5 (2.3) ^b	0.4 (1.9)	0.4 (2.0)
MDGA score	Week 52, mean	0.73	0.58	0.65
	Week 60, mean	0.73	0.75	0.73
	Mean change (SD) ^a	0 (0.31)	0.17 (0.54)	0.08 (0.39)
Active joint count	Week 52, mean	2.8 ^b	2.3	1.7
	Week 60, mean	3.2 ^b	3.3	2.4
	Mean change (SD) ^a	0.4 (3.9) ^b	1.0 (4.9)	0.7 (3.5)

FIG. 59B

	Placebo (n=67)	Anifrolumab 300 mg (n=85)	Anifrolumab 1000 mg (n=75)
Patients with >1 flare, n(%)	2(3.0)	15(17.6)	7(8.2)
Number of flares per patient, n(%)			
0	65(97.0)	70(82.4)	68(90.7)
1	1(1.5)	14(16.5)	7(9.3)
2	1(1.5)	1(1.2)	0(0)
Annualized flare rate per patient, mean (SD)	0.292(1.771)	1.188(2.687)	0.585(1.841)

SD, standard deviation.